Multiply Labs
Multiply Labs
Multiply Labs, leveraging UR cobots, has developed a groundbreaking robotic cluster that is fundamentally transforming the manufacturing of life-saving cell and gene therapies. The Multiply Labs solution drives a staggering 74% cost reduction and enables up to 100x more patient doses per square foot of cleanroom. This efficiency is achieved while significantly enhancing quality, repeatability, and sterility compared to traditional manual processes. Multiply Labs chose Universal Robots due to their human-like performance, crucial six-axis capabilities, unrivaled force mode for delicate handling, seamless software integration, robust community support, and cleanroom compatibility.
For years, the production of personalized cell and gene therapies—treatments derived from a patient's own cells to combat diseases like blood cancers such as lymphoma and leukemia—has been "surprisingly manual, almost artisanal" says Fred Parietti, co-founder and CEO of Multiply Labs. "Expert scientists perform hundreds of tasks by hand, from pipetting to shaking cells." Unlike mass-produced drugs, these treatments are customized for each patient and often priced between $300,000 and $2 million per dose.
Crucially, any microbial contamination makes the entire product unusable, as it cannot be sterilized without killing the therapeutic cells. Given the high cost of each dose, any manufacturing failure is costly. "It absolutely is not scalable to reach the numbers of patients who need these medicines. We quickly realized that robots could really help here,” says Parietti.
Multiply Labs' solution is a modular robotic cluster featuring multiple Universal Robot arms working in parallel, stacked floor-to-ceiling with collision avoidance, designed to faithfully replicate existing manual processes.
The efficacy of this robotic approach has been rigorously validated in peer-reviewed studies with leading institutions like UCSF and Stanford (links to these studies can be found at the end of the page). "Where we compared a traditional manual manufacturing process for these cell therapies to a robotic process doing the exact same process, we found a cost reduction of approximately 74%," says Jonathan Esensten, M.D, PhD. and Director of the Advanced Biotherapy Center at Sheba Medical Center (formerly physician-scientist at UCSF). He called the findings a “quantum leap” leap in terms of being able to manufacture these medicines at a lower cost, and in a smaller space.
By eliminating the need for human involvement and allowing instruments to be stacked, robots also overcome spatial constraints that limit manual operations. “In our estimates we are doing up to 100x more patient doses per square foot of cleanroom,” says Parietti.
Beyond cost and footprint, the robotic system significantly reduces variation in key process parameters, achieving much tighter error bounds than human operators and sub-millimeter accuracy (0.1mm). Sterility is also vastly improved. "Robots don't breathe, and they don't touch stuff they're not supposed to touch," says Parietti. A finding confirmed in the research revealing that while contamination was observed in manual processes, "we did not see any contamination in the robotic process," confirms Dr. Esensten.
A cornerstone of Multiply Labs' innovation is its ‘imitation learning’ technology. This approach ensures the robots don't dictate a new process but instead learn from expert human demonstrations. Multiply Labs asks the pharmaceutical companies they work with to videotape their scientists performing the tasks. This data is fed to the cobots, and the cobots learn to effectively replicate what scientists were doing in the lab. “Just more efficiently, more repeatably, 24/7, and in parallel,” says Parietti. “This method allows our cobots to self-learn 100 new tasks. It’s the key to scaling.”
Jonathan Esensten, Director, Advanced Biotherapy Center, Sheba Medical CenterWhere we compared a traditional manual manufacturing process for these cell therapies to a robotic process doing the exact same process, we found a cost reduction of approximately 74%. That is a quantum leap in terms of being able to manufacture these medicines at a lower cost, and in a smaller space.
The robotic system's ability to precisely replicate established manual methods offers a critical advantage for regulatory compliance. As Dr. Esensten explains: "If a pharmaceutical company has an approved product, it really can’t make major changes to the manufacturing process. By using robots to faithfully execute an already approved process, companies can potentially "save decades and billions of dollars" by avoiding the need to re-approve an entirely new manufacturing method.
Multiply Labs explicitly sought collaborative robots for their human-like performance. After evaluating various options, Universal Robots emerged as "the clear winner", says Nadia Kreciglowa, Head of Robotics Software at Multiply Labs. The intricate manipulations required for cell therapy demanded more than simple 3-axis SCARA robots, leading her team to UR's fully articulated 6-axis robotic arms. Multiply Labs further integrated these into an 8-degree-of-freedom system with rails for broader movement.
A pivotal factor was UR's unrivaled integrated force sensing, which mimics human tactile feedback. This crucial feature was essential for handling delicate and expensive components without breakage. “It saved us months of development time," recalls Kreciglowa, who also highlights UR's seamless software integration with various control options, including extensive Python interfaces. She had initially feared the teach pendant's simple interface was limiting. “But we discovered UR offered a lot of different options for robust control, with rich documentation and online tutorials."
The vast UR user community and ecosystem also proved invaluable. “UR's compatibility with external tools like RoboDK, NVIDIA Isaac simulation, and AI models, along with readily available integrations for custom end effectors, camera sensors, and other components, was a huge advantage,” says Parietti.
Multiply Labs' robotic clusters are already deployed in commercial partners' facilities. “The clusters deliver astonishing levels of efficiency, throughput, and repeatability,” says Parietti, describing the robots as having "superhuman performance". According to Dr. Esensten, Multiply Labs’ cluster "will really change the way we think about the manufacturing of these bespoke, custom cell and gene therapies for patients, ultimately improving patient access globally.”
The efficacy of this robotic approach has been rigorously validated in studies with leading institutions like UCSF and Stanford.
Thousands of businesses rely on Collaborative Robots to...